

RESEARCH ARTICLE

Hydroxychloroquine Prophylaxis for COVID-19

Author

David D. Busath, M.D.

Professor of Physiology and Biophysics (retired), Brigham Young University, Provo, UT 84602

Email: david_busath@byu.edu , 801 369-6366

Abstract

It is common in medicine that simple, inexpensive remedies are held hostage to medical prejudice, financial or political interest, and legal precedent. The purpose of this review is to take the point of view of the victims of COVID-19 and address whether scientific information, including randomized-control trials, can answer whether the hydroxychloroquine should be dispensed for those testing positive and their immediate recent contacts at the point of testing. Although the FDA in the United States is yet to be convinced, the demonstration of positive effects in clinical trials cannot be ignored and there is a large amount of information in the pipeline (published pre-prints and registered clinical trials) that could tip the scales towards making the drug readily available for early disease and contact-prophylactic usage to reduce peak symptoms, symptom duration, contagiousness, hospitalizations and mortality.

In the past few years, the original promise of the influenza neuraminidase inhibitor oseltamivir (Tamiflu), has been realized in many states in the USA that now allow it to be dispensed in pharmacies, often in conjunction with rapid diagnostic testing (1). This has been facilitated by the termination of patent rights and development of generics, but inhibited by bias in the medical community, which is familiar with clinical trials confirming their experience that oseltamivir only shaves a day or two off of symptoms when administered “within 36 hours” of the onset of symptoms (2) and the ethical and clinical complexities (3). Physicians may be less familiar with the carefully controlled human influenza exposure experiments demonstrating that if given the day before or day after infection, it dramatically reduces the magnitude and duration of symptoms (4). Influenza has a short incubation period (1-2 days) and even when administered at the onset of symptoms, oseltamivir is very effective. Later treatment is not effective because the symptoms are mainly an expression of the immune system inflammation, which is usually sufficiently effective to confine and eliminate the virus in the lungs.

When the COVID19 pandemic began, hydroxychloroquine (HCQ) and chloroquine were rational choices for prophylaxis. With a modest *in vitro* potency and low cytotoxicity for SARS-COV2 (5-8), about one tenth as strong as oseltamivir’s potency against influenza, basic scientists projected that it might be weak, but available and useful in reducing symptoms if given early in the infections. Its possible role in a respiratory

virus pandemic situation had been discussed for over a decade.

Early clinical trials of HCQ for COVID19 were undertaken where it was most convenient, i.e. with hospitalized patients. Focusing here on peer-reviewed publications, most reports were for retrospective observational or cohort studies and some showed good reduction of infection rate, hospital course, and/or death (9-17) while others showed little or no effect (18-23). An editorial in *Science* (24) citing the negative conclusion of the Recovery trial at Oxford proclaimed that only large RCTs should be trusted. But in this scenario, reproducibility in observational studies clearly justified further study.

A preprint report of one of the latter studies posted on April 23, (now published (20)), which is a retrospective cohort analysis of COVID19 patients in all US Veteran Affairs hospitals admitted up until April 11, yielded higher mortality for the HCQ arm than the standard of care arm and caused a large academic and public reaction. Coinciding with increasing concerns about long QT arrhythmia risk at high doses in a phase IIb HCQ trial in Brazil published on April 24 (25), some clinical trials were discontinued or put on hold. Several studies of QT prolongation in hospitalized patients subsequently showed only modest QTc prolongation for patients on HCQ with no cases of *torsades de pointes* (26-30). A safety review concluded that “HCQ should not be restricted in COVID-19 patients out of fear of cardiac morality” (31). After a period of time, some clinical trials resumed but many of these have reported poor enrollment due to the

negative publicity that week. One carefully executed randomized control trial showed no reduction in viral RNA load for non-hospitalized patients, but results may have been diluted by using patients with up to five days of symptoms at enrollment (32).

Early hopes that a prophylactic effect of HCQ were suggested by a use in an outbreak situation in a Korean hospital (33), a small study in Hubei province, China (34), and a low case frequency in countries where malaria is endemic (35). One might hope to find a prophylactic effect in patients taking it continuously for systemic lupus erythematosus or rheumatoid arthritis, but by mid-June these hopes were doused by reports of COVID19 appearing in these populations taking HCQ with frequencies similar to those not (36), consistent with a massive study published July 8 of the similar incidences of COVID19 in rheumatoid (a large fraction presumably taking HCQ) vs. non-rheumatoid groups (37). However, these apparent neutral results do not account for an increased incidence of COVID-19 in rheumatoid patients, which when considered yielded a protective effect of HCQ (38). Furthermore, a retrospective study of rheumatoid patients in Portugal demonstrated a significant reduction in COVID-19 vulnerability in HCQ users (39).

Prophylaxis (40) and early treatment (41) RCTs carried out by internet recruitment and overnight-shipped tablets (HCQ or folic acid placebo) showed no or modest effects, respectively. The World Health Organization discontinued the Solidarity later treatment trial for “little or no reduction in mortality.” Subsequently, numerous additional

observational studies and RCTs, including a few pre- and post-exposure prophylaxis and early treatment have been published. Most have demonstrated positive effects (42-56) and a few have shown little or no effect (57-62). Some of the clinical trials have been analyzed for bias potential with stringent criteria (63-65), but an ever-present possibility of editorial bias. The recent studies show persuasive, reproducible benefits of HCQ in humans against COVID-19.

Animal studies showed that HCQ is ineffective against SARS-COV2 infections instilled in ferrets (66), and cynomolgus macaques (67). The ferrets were treated one day post-infection and showed some reduction of inflammation signs, but viral load was unaffected. The monkeys were treated either one hour after or seven days before infection and showed no reduction in viral load in the early treatment case, nor reduction in infection rate in the pre-exposure prophylaxis case. In conjunction with the macaque study, it was also shown that a human airway epithelium model derived from biopsies was not protected from SARS-COV2 infection by HCQ (67).

On June 15, the FDA in the USA revoked its emergency use authorization for HCQ out of concerns over cardiotoxicity, as suggested in an informative but pessimistic April 20 review (68). They currently recommend that HCQ only be used for COVID19 under the auspices of a registered clinical trial. Medical institutions and pharmacies reigned in the physicians who believed HCQ was useful and were prescribing it as routine practice. This drew a law suit from the American Association of

Physicians and Surgeons against the FDA (pending in federal court in Grand Rapids, Michigan, *AAPS v. FDA, et al.*, 20-cv-493) and stimulated the formation of the American Frontline Physicians who were persuaded of the HCQ clinical merits from their personal experience. Stephen Hatfill, a bioterrorism expert, and Harvey Frisch, an epidemiologist, weighed in on August 4 in a RealClear Politics article and August 23 in a television interview, respectively, that there are many clinical trials that show a benefit for HCQ in COVID19, and that it has not yet been tested for prophylactic effect in vulnerable populations. Most studies so far have focused on critically ill late-stage inpatients, or slightly ill young healthy outpatients. Perhaps prophylaxis for vulnerable subjects is where HCQ will prove effective (69). On one hand, a strong argument about the inadequacy of standard dosing and cardiotoxicity at adequate dosing was published on August 17 (70). On the other hand, national use of HCQ correlates with reduced nation case fatality rates (71).

At this point (September 29, 2020), we can say with confidence that HCQ does not immediately reverse COVID19 for hospitalized patients, but it also doesn't cause increased mortality (reference (20) notwithstanding), and for some it may be helpful. We can say that taking HCQ chronically for rheumatological disease may or may not protect one appreciably, but the negative results may be confounded by high vulnerability of such patients to COVID-19, or perhaps chronic use may lead to cellular adaptation. In young healthy infected respondents to on-line surveys, it is moderately better than placebo for reducing symptoms and the chance of hospitalization,

although statistical significance wasn't achieved (41).

But yet needed are the kinds of studies that could motivate the health care industry and the FDA to make HCQ available at the point of rapid SARS-COV2 testing. It is easy to imagine that such studies might yet appear. For instance, given the low risk of severe disease in healthy young adults, it is easy to imagine a research experiment like the original oseltamivir experiment where 100 individuals are recruited to isolate in hotel rooms and get exposed to SARS-COV2 with HCQ or placebo. No such experiment is currently being contemplated to my knowledge.

More immediately, we eagerly await the publication of many registered pre-print reports of clinical trials. An excellent summary of this literature, as well as plots of global use of HCQ and COVID-19 incidence divided by nations that allow HCQ use and those that limit it, can be found at c19study.com. The count of positive-effect pre-print reports greatly exceeds that of non-effect reports, but these are yet to be peer-reviewed, evaluated for bias-potential, and weighed for significance as they relate to cost, risk, and benefit.

We also await the results of more registered clinical trials for HCQ used as early and prophylactic treatment against COVID19. As of August 25, there were 247 clinical trials registered at clinicaltrials.gov identified with the keywords "COVID19, hydroxychloroquine." Of particular interest are the 67 selected with the keywords "COVID19, hydroxychloroquine, prophylaxis." Of these, 25 have titles

indicating that they are focused on the use of HCQ prophylaxis in health care workers for COVID19, namely NCT04435808, NCT04364815, NCT04303507, NCT04438837, NCT04437693, NCT04352946, NCT04363450, NCT04377646, NCT04333225, NCT04354597, NCT04336748, NCT04370015, NCT04345653, NCT04384458, NCT04374942, NCT04340349, NCT04334928, NCT04354870, NCT04318015, NCT04371926, NCT04347889, NCT04328285, NCT04346329, NCT04334148, NCT04371523. In addition, there were 60 trials in the WHO COVID19 Registry retrieved with the keywords “chloro, prophyl” or “chlor outpatient” (where keywords can be parts of words). Although many studies have been canceled out of fear of cardiotoxicity in the investigators or potential subjects, it is possible that some will yet be completed in the next 6 months or so, as many originally projected.

There are also a few prophylaxis studies underway in vulnerable populations, such as nursing homes. These include the PREVICHARM trial (NCT04400019), a Canadian study (NCT04397328), a multicenter study based in Chicago, New Orleans, Boston and other sites (NCT04354428), and the French OUTCOV study (NCT04365582). The first two of these were retrieved from clinicaltrials.gov with the keywords stated above, and the second two with the keyword “prophylaxis” replaced with “outpatient.” These vulnerable population studies are the most difficult to arrange, not just because of ethical concerns that such

subjects would be more sensitive to long QT syndrome, or at least to the dehydration that could accompany any vomiting associated with nausea and diarrhea, common initial side effects of HCQ, but also because nursing homes could be hard to place under the watch of internal review boards from hospitals, universities, or other large institutions. But, these may be the most important studies yet to be done, because the world is most frozen by the fear of COVID19 wiping out these vulnerable populations *en masse*. The level of concern for the vulnerable is demonstrated by the arguments that children, teens, and college students should wear masks at school and healthy adults should wear masks to the grocery store and workplace when neither group is likely to have deadly illness if they contract COVID19.

However, the larger set of prophylaxis studies with health care workers is probably most important for the question of whether states should allow pharmacies to dispense HCQ under a standing doctor’s order for clients with positive rapid SARS-COV2 saliva tests. Only if HCQ safely flattens the curve for healthy individuals on a personal-symptoms level sufficient to impress the FDA would HCQ be appropriately dispensed at pharmacies. In many countries, HCQ is available over the counter for malaria prophylaxis. One can hope that the FDA will soon be convinced to make HCQ, readily available to the common victims of COVID-19. Then whether it is done under a doctor’s standing order prescription at pharmacies and sites that perform rapid testing or just over-the-counter would be up to state legislatures.

References

1. Klepser ME, Adams AJ. 2018. Pharmacy-based management of influenza: lessons learned from research. *The International journal of pharmacy practice* 26:573-8
2. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, et al. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. *JAMA* 283:1016-24
3. Hurt AC, Kelly H. 2016. Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza. *Emerg Infect Dis* 22:949-55
4. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, et al. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza - Randomized controlled trials for prevention and treatment. *Jama-Journal of the American Medical Association* 282:1240-6
5. Wang M, Cao R, Zhang L, Yang X, Liu J, et al. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 30:269-71
6. Touret F, Gilles M, Barral K, Nougairede A, van Helden J, et al. 2020. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. *Sci Rep* 10:13093
7. Weston S, Coleman CM, Haupt R, Logue J, Matthews K, et al. 2020. Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. *J Virol*
8. Liu J, Cao RY, Xu MY, Wang X, Zhang HY, et al. 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery* 6:1-4
9. Huang M, Tang T, Pang P, Li M, Ma R, et al. 2020. Treating COVID-19 with Chloroquine. *J Mol Cell Biol* 12:322-5
10. Gautret P, Lagier JC, Parola P, Hoang V, Meddeb L, et al. 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents* 56
11. Sánchez-Álvarez JE, Fontán MP, Martín CJ, Pelicano MB, Reina CJ, et al. 2020. Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). *Nefrología (English Edition)* 40:272-8
12. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, et al. 2020. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. *Travel Med Infect Dis* 35:101738
13. Okour M, Al-Kofahi M, Austin D. 2020. Hydroxychloroquine and

- azithromycin as potential treatments for COVID-19; clinical status impacts the outcome. *J Pharmacokinet Pharmacodyn* 47:187-8
14. Yu B, Li C, Chen P, Zhou N, Wang L, et al. 2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. *Sci China Life Sci*
 15. Huang M, Li M, Xiao F, Pang P, Liang J, et al. 2020. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. *National Science Review* 7:1428-36
 16. Ayerbe L, Risco C, Ayis S. 2020. The association between treatment with heparin and survival in patients with Covid-19. *J Thromb Thrombolysis* 50:298-301
 17. Wonner M, Andreis NR-d, Sarrazin E, Lacrosse P, Lardenois T, et al. 2020. Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19. *Asian Journal of Medicine and Health*:45-55
 18. Chen J, Liu D, Liu L, Liu P, Xu Q, et al. 2020. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 49:215-9
 19. Tang Wea. 2020. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. *medRxiv Preprint*
 20. Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, et al. 2020. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. *Med* 1:1-14
 21. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, et al. 2020. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 382:2411-8
 22. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, et al. 2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA* 323:2493-502
 23. Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, et al. 2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. *BMJ* 369:m1844
 24. Kupferschmidt K. 2020. U.K. megatrial outshines other drug studies. *Science* 369:124-5
 25. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. 2020. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Netw Open* 3:e208857

26. Mercurio NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, et al. 2020. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 5:1036-41
27. Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, et al. 2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. *J Am Heart Assoc* 9:e017144
28. Bessiere F, Rocchia H, Deliniere A, Charriere R, Chevalier P, et al. 2020. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. *JAMA Cardiol* 5:1067-9
29. Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, et al. 2020. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. *Circ Arrhythm Electrophysiol*
30. Bakhshaliyev N, Uluganyan M, Enhos A, Karacop E, Ozdemir R. 2020. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. *J Electrocardiol* 62:59-64
31. Prodromos CC, Rumschlag T, Perchyk T. 2020. Hydroxychloroquine is protective to the heart, not harmful: a systematic review. *New Microbes New Infect* 37:100747
32. Mitja O, Corbacho-Monne M, Ubals M, Tebe C, Penafiel J, et al. 2020. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. *Clin Infect Dis* In press
33. Lee SH, Son H, Peck KR. 2020. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? *Int J Antimicrob Agents* 55:105988
34. Zhong J, Shen G, Yang H, Huang A, Chen X, et al. 2020. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. *The Lancet Rheumatology* 2:e557-e64
35. Meo SA, Klonoff DC, Akram J. 2020. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. *Eur Rev Med Pharmacol Sci* 24:4539-47
36. Romão VC, Cruz-Machado AR, Fonseca JE. 2020. Mounting data indicate that antimalarials do not prevent mild or severe COVID-19 in rheumatic patients. Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al. *Ann Rheum Dis*
37. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, et al. 2020. Factors associated with COVID-19-

- related death using OpenSAFELY. *Nature* 584:430-6
38. Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, et al. 2020. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. *Clin Rheumatol*
39. Ferreira A, Oliveira ESA, Bettencourt P. 2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. *J Med Virol*
40. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, et al. 2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med* 383:517-25
41. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, et al. 2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. *Ann Intern Med*
42. Pirnay G, Dantier B, Tourid W, Terkemani A, Bachot F, et al. 2020. Effet bénéfique de l'association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d'une étude observationnelle. *Le Pharmacien Hospitalier et Clinicien*
43. Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, et al. 2020. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. *Travel Med Infect Dis*:101791
44. Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, et al. 2020. Risk Factors for Mortality in Patients with COVID-19 in New York City. *J Gen Intern Med*
45. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, et al. 2020. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *Int J Infect Dis* 97:396-403
46. Hong KS, Jang JG, Hur J, Lee JH, Kim HN, et al. 2020. Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication. *Infect Chemother*
47. d'Arminio Monforte A, Tavelli A, Bai F, Marchetti G, Cozzi-Lepri A. 2020. Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal? *Int J Infect Dis* 99:75-6
48. Davido B, Boussaid G, Vaugier I, Lansaman T, Bouchand F, et al. 2020. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. *Int J Antimicrob Agents* 56:106129
49. Yu B, Li C, Chen P, Li J, Jiang H, Wang DW. 2020. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. *Sci China Life Sci*
50. Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, et al. 2020. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. *Cancer Discov*

51. Dubernet A, Larsen K, Masse L, Allyn J, Foch E, et al. 2020. A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Reunion Island. *J Glob Antimicrob Resist* 23:1-3
52. Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, et al. 2020. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. *Int J Antimicrob Agents* 56:106144
53. Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, et al. 2020. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. *Eur J Intern Med* In press.
54. Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, et al. 2020. Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran. *Tohoku J Exp Med* 252:73-84
55. Bruno Heberto A, Corona Juan Carlos P, Rubio Jose Antonio C, Perez Patricia P, Rasgado Enrique T, et al. 2020. Implications of Myocardial Injury in Mexican Hospitalized Patients with Coronavirus Disease 2019 (Covid-19). *Int J Cardiol Heart Vasc* 30:100638
56. Lauriola M, Pani A, Ippoliti G, Mortara A, Milighetti S, et al. 2020. Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients. *Clin Transl Sci*
57. Giacomelli A, Pagani G, Ridolfo AL, Oreni L, Conti F, et al. 2020. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. *J Med Virol*
58. Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, et al. 2020. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. *Cancer Discov*
59. Kelly M, O'Connor R, Townsend L, Coghlan M, Relihan E, et al. 2020. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. *Br J Clin Pharmacol*
60. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, et al. 2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med*
61. Lopez A, Duclos G, Pastene B, Bezulier K, Guilhaumou R, et al. 2020. Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results. *Int J Antimicrob Agents*:106136
62. Lecronier M, Beurton A, Burrel S, Haudebourg L, Deleris R, et al. 2020.

- Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. *Crit Care* 24:418
63. Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. 2020. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. *Ann Intern Med*
64. Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. 2020. Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. *Ann Intern Med*
65. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. 2020. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*
66. Park SJ, Yu KM, Kim YI, Kim SM, Kim EH, et al. 2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. *mBio* 11
67. Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, et al. 2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. *Nature*
68. Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, et al. 2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. *FASEB J* 34:6027-37
69. McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, et al. 2020. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. *Am J Med*
70. Kashour T, Tleyjeh IM. 2020. It is time to drop hydroxychloroquine from our COVID-19 armamentarium. *Medical Hypotheses* 144:110198
71. Elbazidi H, Erraih O. 2020. Pandemic and social changes, political fate. *New Microbes New Infect*:100749